tbuckley/cabot-search huggingface dataset:
1133P Additional practice-informing adverse event patterns and management in the KRYSTAL-1 phase II study of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC
Authors: J. Zhang, K. Leventakos, T.A. Leal, N. Pennell, M. Barve, A.S. Paulson, L. Bazhenova, M.L. Johnson, R.C. Chao, K. Velastegui, C. Qian, W. Bleker, A. Spira
Journal: Annals of Oncology (2022)
1138P Alternate pembrolizumab dosing interval in advanced NSCLC with PD-L1 &gt;/= 50%: 3 weekly compared to 6 weekly dosing
Authors: L. Jones, R. Rittberg, B. Leung, A. Shokoohi, A. Pender, S. Wong, Z.S. Al-Hashami, Y. Wang, C. Ho
Journal: Annals of Oncology (2022)
1115P Amivantamab vs real-world (RW) therapies for advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutation (E20i) in Japan
Authors: M. Okahisa, H. Udagawa, S. Matsumoto, T. Kato, H. Yokouchi, N. Furuya, R. Kanemaru, R. Toyozawa, A. Nishiyama, K. Ohashi, S. Miyamoto, K. Nishino, H. Oi, G.K.M. Low, J. Zhuo, D. Young Yu, Y. Yang, C. Lim, N.J. Kleinman, K. Goto
Journal: Annals of Oncology (2022)
1126P Project LUMINATE-101: Real-world outcomes of EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (aNSCLC) patients receiving docetaxel post frontline (1L) platinum-based chemotherapy in combination with pembrolizumab
Authors: D.R. Camidge, S. Karve, Q. Xu, S. Ng, R. Kamalakar, C.K. Ratajczak, S. Lu
Journal: Annals of Oncology (2022)
1296MO PRODIGE 29-UCGI 26(NEOPAN): A phase III randomised trial comparing chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (LAPC)
Authors: M.P. Ducreux, R. Desgrippes, Y. Rinaldi, F. Di Fiore, R. Guimbaud, P. Follana, J-B. Bachet, P. Vanelslander, T. Lecomte, O. Capitain, A. Parzy, M. Bolliet, P-L. Etienne, J. Forestier, F. El Hajbi, A.L. Bignon Bretagne, V. Ly Lebrun, N. De Sousa Carvalho, M. Texier, O. Bouche
Journal: Annals of Oncology (2022)
1246P Multicenter phase Ib/II study of second-line varlitinib and paclitaxel in patients with EGFR/HER2 co-expressing advanced gastric cancer (K-MASTER-13)
Authors: M. Jung, Y.H. Kim, H.C. Jeung, D.Y. Zang, W.K. Bae, D-H. Koo, H. Kim, H.S. Kim, C-K. Lee, H.C. Chung, S.Y. Rha
Journal: Annals of Oncology (2022)
1278P How do hospitalized patients with chronic liver disease, with and without hepatocellular carcinoma, die? End-of-life quality analysis
Authors: A.C. Bravo, C.N. Nascimento, B. Abreu, J. Revés, B. Morão, C. Frias-Gomes, M. Canhoto, L. Glória, C.A. Fidalgo
Journal: Annals of Oncology (2022)
1192TiP GALLANT-1: Galectin-3 (Gal-3) inhibitor, GB1211, plus atezolizumab (atz) in patients (pts) with non-small cell lung cancer (NSCLC) - a dose finding study followed by a randomised, double-blind, placebo-controlled trial
Authors: F. Ghiringhelli, P. Barre, E. Pichon, S. Ponce Aix, O.J. Juan Vidal, E. Carcereny Costa, T. Sethi, B. Lindmark, A. MacKinnon, V. Aslanis, D.H. Phung, P. Jensen, Z. Rajiwate, G. Ross, L. Basse
Journal: Annals of Oncology (2022)
1213P DKN-01 and tislelizumab + chemotherapy as first-line (1L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
Authors: S.J. Klempner, J. Chao, H. Uronis, C. Sirard, M. Kagey, J. Baum, J. Song, J. Wang, M.B. Sonbol, Z.A. Wainberg, J.A. Ajani
Journal: Annals of Oncology (2022)
1340P Trends in access to early phase clinical trials in underserved populations during the COVID-19 pandemic
Authors: J. Balmaceda, D.P. Mudaranthakam, G. Doolittle, W. Sun, H. Krebill, T. Lin, A. Jewell, A. Saeed, S. Abbasi, R. Jensen, J.C. Baranda
Journal: Annals of Oncology (2022)
1227P Regorafenib (REGO) with nivolumab (NIVO) and FOLFOX in HER2 negative esophagogastric cancer (EGC)
Authors: S. Cytryn, None S. joshi, G.Y. Ku, S.B. Maron, A. Desai, J. Yang, D. Rao, Z. Goldberg, R. Sugarman, A. Antoine, F. Socolow, J.F. Chou, M. Capanu, H. Gerdes, M. Simmons, V. Paroder, L. Tang, J. Shia, D.H. Ilson, Y.Y. Janjigian
Journal: Annals of Oncology (2022)
1114P Long-term outcome in Danish real-life patients with advanced non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors
Authors: B. Bjornhart, M. Mouritzen, C. Kristiansen, K.H. Holmskov, K. Wedervang, T.L. Jorgensen, J. Herrstedt, M. Pohl, T. Schytte
Journal: Annals of Oncology (2022)
1105P Outcomes of real-world (RW) patients (pts) with advanced NSCLC (aNSCLC) and high programmed cell death-ligand 1 (PD-L1) expression receiving first line (1L) immune checkpoint inhibitor (ICI) therapy
Authors: M.L. Hsu, W. Ge, N. Wu, R. Quek, J. Liu, J.J. Jalbert, P. Rietschel, J. Feliciano, J. Harnett
Journal: Annals of Oncology (2022)
1188TiP ORCHARD platform study: Osimertinib + datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib
Authors: J. De Langen, B.C. Cho, Z. Piotrowska, X. Le, S.B. Goldberg, J.W. Goldman, I. Okamoto, N. Hewson, J. Maidment, K.H. Tang, N. Veney, J. Cosaert, J. Lau, M. Dressman, H. Ambrose, J.W. Riess, H.A. Yu
Journal: Annals of Oncology (2022)
1185TiP First-in-human phase I study of ABBV-637 as monotherapy and in combination in patients with relapsed and refractory solid tumors
Authors: J. Rotow, K. Yoh, J.D. Powderly, T. Shimizu, R. Perets, L. Paz-Ares, A. Phillips, A. Souers, P.J. Ansell, J. Jin, M. Badawi, R. Saab, G. Morrison-Thiele, S. Jeffries, M.R. Neagu Aristide, B.A. Carneiro, K.P. Papadopoulos
Journal: Annals of Oncology (2022)
1255P da VINci: Safety and efficacy of the OTSGC-A24 vaccine and nivolumab in metastatic gastric cancer
Authors: J. Choo, S.Y. Rha, M. Jung, H.L. Tan, G. Chan, J.S. Ho, R.J. Walsh, C.E. Chee, S. Raghav, W.P. Yong
Journal: Annals of Oncology (2022)
1127P Efficacy of current immunotherapies in patients (pt) with metastatic non-small cell lung cancer (NSCLC) harboring KRAS mutations
Authors: L. Notario Rincon, A. Pous, A. Lopez Paradis, A. Notario, M. Cucurull Salamero, A. Hernandez Gonzalez, M. Domenech Vinolas, E. Carcereny Costa, M.T. Moran Bueno, A. Muñoz, J.L. Mate, C. Sanz, M. Saigi Morgui
Journal: Annals of Oncology (2022)
1152P Lung cancer metastasis patterns and racial disparities: A SEER database population study 2010–2018
Authors: A.R.A. Armashi, F. Hammad, A.M.S. Al Zubaidi, D. Elantably, K. Patell, F. Somoza-Cano, M. Homeida, M.P. Cruz Peralta, K. Ravakhah, A. Alkrekshi
Journal: Annals of Oncology (2022)
1265MO Cause and place of death in older patients with cancer: Results from a large cohort study using linked clinical and population-based data
Authors: V. Depoorter, K. Vanschoenbeek, L. Decoster, H. De Schutter, P.R. Debruyne, I. De Groof, D. Bron, F. Cornelis, S. Luce, C. Focan, V. Verschaeve, G. Debugne, C.M. Langenaeken, H.F.M. van den Bulck, J-C. Goeminne, K. Milisen, J. Flamaing, C. Kenis, F. Verdoodt, H. Wildiers
Journal: Annals of Oncology (2022)
1335P Using adaptive health technology assessment (aHTA) to assess the potential cost-effectiveness of pembrolizumab and palbociclib in the Indian context
Authors: M. Sengar, P. Ranganathan, A. Ashok, J. Thorat, P. Nayak, T. Wahid, C. Nemzoff, S. Ghosh, F. Ruiz, A. Mehndiratta, C.S. Pramesh
Journal: Annals of Oncology (2022)
1121P Real-world (RW) data from the sotorasib French pre-market authorization early access program in patients (pts) with KRASG12C driven metastatic non-small cell lung cancer (mNSCLC): Clinical characteristics
Authors: J. Cadranel, X. Quantin, N. Girard, F. Barlesi, J.B. Auliac, S. Couraud, A-C. Madroszyk Flandin, L. Pabst, C. Rieux, H. Curcio, R. Gille, A-C. Métivier, C. Becht, O. Bylicki, P. Tomasini, R. Veillon, C. Damade, C. Mourad, C. Veillard, H. Lena
Journal: Annals of Oncology (2022)
1336P Epidemiology of rare cancers in South Asian Association for Regional Cooperation (SAARC) countries: Remembering the forgotten
Authors: J. Bajpai, S. Mailankody, A. Budukh, R. Swaminathan, R. Dikshit, S. Perera, M. Dhimal, U. Tshomo, S. Bagal, M. Bhise, S. Banavali, S. Gupta, P. Chaturvedi, R. Badwe, A. Trama
Journal: Annals of Oncology (2022)
1248P Identification of Epstein-Barr virus (EBV)-associated gastric cancer at RNA-level by evaluating transcriptional status of seven EBV crucial genes
Authors: J. Yuan, W. Chen, L. Wang, C. Cao, X. Song, J. Zhao, F. Gai, H. Dong, C. Zhu, H. Shi
Journal: Annals of Oncology (2022)
1315O Key learnings from building: A precision cancer medicine implementation initiative for Norway
Authors: K. Tasken, H.G. Russnes, E. Aas, L. Bjorge, E.S. Blix, E. Enerly, L. Fagereng, Å. Flobak, B. Gilje, B.T. Gjertsen, T.K.K. Guren, J. Heix, E. Hovig, R. Hovland, P.E. Lonning, P.M. Mæhle, H.L. Nilsen, S. Thoresen, S. Smeland, A. Helland
Journal: Annals of Oncology (2022)
1094P The clinical potential of circulating-free DNA (cfDNA) for real-time longitudinally monitoring clinical outcomes in a real-world first-line non-small cell lung cancer (NSCLC) prospective study
Authors: V. Gristina, N. Barraco, A. Galvano, M. La Mantia, S. Cutaia, F. Iacono, C. Lisanti, S. Inguglia, D. Sardo, A. Perez, S. Cusenza, L. Castellana, T.D. Bazan Russo, S. Vieni, F. Fulfaro, L. Incorvaia, G. Badalamenti, V. Bazan, A. Russo
Journal: Annals of Oncology (2022)
1302P Gender differences in tumor characteristics, treatment allocation and survival in patients in a real-world non-metastatic pancreatic cancer cohort
Authors: A.M. Gehrels, H. Wilmink, A.D. Wagner, M.G. Besselink, R. Verhoeven, H.C. van Santvoort, B. Groot Koerkamp, H.W.M. van Laarhoven, L. van der Geest
Journal: Annals of Oncology (2022)
1186TiP EPONA, efficacy of osimertinib with platinum and pemetrexed in EGFR mutant non-small cell lung cancer patients bearing CNS metastasis, and have systemic progression but stable intracranial disease on OsimertiNib resistAnce (TORG 1938)
Authors: Y. Okuma, S. Nomura, K. Ninomiya, H. Yamaguchi, S. Murakami, Y. Kogure, D. Harada, K. Okishio, H. Okamoto, Y. Goto
Journal: Annals of Oncology (2022)
1080P Immune checkpoint blockade therapy affects circulating FLIP-expressing monocytic myeloid-derived suppressor cells (M-MDSC) in non-progressor non-small cell lung cancer patients
Authors: L. Belluomini, C. Frusteri, A. Adamo, S. Pilotto, G. Sartori, J. Insolda, M. Sposito, S. Caligola, L. Giacobazzi, O. Poffe, D. Rizzini, A. Vella, C. Carbone, G. Piro, F. De Sanctis, S. Sartoris, S. Canè, M. Milella, V. Bronte, S. Ugel
Journal: Annals of Oncology (2022)
1089P Hepcidin expression as a predictive biomarker for anti-PD1/PDL1 antibody monotherapy for advanced non-small cell lung cancer
Authors: M. Yamamoto, S. Kubo, N. Hirama, S. Teranishi, K. Tashiro, K. Seki, C. Maeda, S. Hiro, Y. Kajita, C. Sugimoto, W. Segawa, H. Nagayama, S. Nagaoka, M. Kudo, T. Kaneko
Journal: Annals of Oncology (2022)
1264MO Development and validation of a unifying pre-treatment decision tool for intracranial and extracranial metastasis-directed radiotherapy
Authors: R.O. Kowalchuk, T.C. Mullikin, W.G. Breen, H.C. Gits, M. Florez, B.S. De, W.S. Harmsen, P.S. Rose, B.L. Siontis, B.A. Costello, J.M. Morris, J.J. Lucido, K.R. Olivier, B.J. Stish, N.N. Laack, S.S. Park, D. Owen, A.J. Ghia, P.D. Brown, K.W. Merrell
Journal: Annals of Oncology (2022)
1156P Quality-adjusted survival with brigatinib (BRG) versus crizotinib (CRZ) in ALK-positive (ALK+) non-small cell lung cancer (NSCLC): Results from the ALTA-1L trial
Authors: M.R. Garcia Campelo, Y. Wan, M. Lin, T. Chen, J. Shen, P. Zhang, M.J. Humphries, D.R. Camidge
Journal: Annals of Oncology (2022)
1337P Implementation of precision oncology in clinical practice: A nationwide survey in Italy
Authors: G. Fasola, M.C. Barducci, G. Pelizzari, G. Aprile, F. Grossi, C. Pinto, B. Daniele, M. Giordano, C. Ortega, R.R. Silva, V. Tozzi, L. Cavanna
Journal: Annals of Oncology (2022)
1277P The role of palliative care in patients with glioblastoma multiforme: A single centre review
Authors: A. McGarry, A. Ni Nualláin, T. Byrne, J. O'Brien, C. Rice, O. Breathnach, W. Grogan, C. McAleer, R. McQuillan, None McNally, E. Cowie
Journal: Annals of Oncology (2022)
1183P Patient-reported outcomes (PROs) of cemiplimab vs chemotherapy in advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 1 histology subgroups
Authors: A. Sezer, S. Kilickap, M. Gumus, I. Bondarenko, M. Ozguroglu, M. Gogishvili, X. He, G. Gullo, P. Rietschel, R. Quek
Journal: Annals of Oncology (2022)
1164P Patient-reported outcomes in patients with advanced NSCLC before and during the COVID-19 pandemic in the German prospective CRISP Registry real-world cohort (AIO-TRK-0315)
Authors: M. Sebastian, F. Griesinger, E. von der Heyde, S. Dörfel, J.H. Wiegand, C. Schiefer, C. Losem, M. Jänicke, A. Fleitz, S. Zacharias, A. Hipper, C. Dietel, A. Bleckmann, R. Benkelmann, M. Boesche, C. Grah, A. Müller, W.E.E. Eberhardt, M. Thomas
Journal: Annals of Oncology (2022)
1196TiP LuCa-MERIT-1: First-in-human, open label, phase I dose confirmation trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer
Authors: P.M. Forde, A. Atmaca, P. Brück, N. Munshi, M.A. Kaczorowska, T. Schell, Ö. Türeci, U. Sahin
Journal: Annals of Oncology (2022)
1298P Extended overall survival results from the POLO study of active maintenance olaparib in patients with metastatic pancreatic cancer and a germline BRCA mutation
Authors: P. Hammel, T. Golan, M. Reni, E. Van Cutsem, T. Macarulla Mercade, M. Hall, J.O. Park, D. Hochhauser, D. Arnold, D-Y. Oh, A. Reinacher-Schick, G. Tortora, H. Algül, E. O'Reilly, K. Sharan, X. Ou, K.Y. Cui, G. Locker, H. Kindler
Journal: Annals of Oncology (2022)
1338P Cost-effectiveness and direct impact analysis of clinical research in the clinical approach of metastatic renal cell carcinoma and neuroendocrine tumors in a large public Spanish university hospital
Authors: S. García-Garro, P. Gajate Borau, E. Gómez de Salazar, T. Alonso Gordoa, M.Á. Rodriguez Sagrado, J. Molina Cerrillo, L. Manzano Espinosa, T. Bermejo Vicedo, A. Carrato Mena, J.J. Díez Gómez, E. Grande Pulido
Journal: Annals of Oncology (2022)
1195TiP HERTHENA-Lung02: A randomized phase III study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC after progression with a third-generation EGFR TKI
Authors: T.S.K. Mok, Y-L. Wu, M. Nishio, M. Reck, E. Wu, D.W. Sternberg, S. Esker, H.A. Yu
Journal: Annals of Oncology (2022)
1204MO PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
Authors: D. Tougeron, L. Dahan, F. El Hajbi, K. Le Malicot, L. Evesque, T. Aparicio, O. Bouche, N. Bonichon Lamichhane, B. Chibaudel, A. Angelergues, None A. bodere, J.M. Phelip, M. Mabro, P. Artru, C. Louvet
Journal: Annals of Oncology (2022)
1143P Effect of best response to first-line (1L) treatment (tx) on outcomes with second-line (2L) nintedanib (NIN) + docetaxel (DOC) for patients (pts) with lung adenocarcinoma after 1L immune checkpoint inhibitor (ICI) combination therapy
Authors: C. Grohé, T.C. Wehler, S. Henschke, I. Dittrich, S. Hammerschmidt, C. Aulmann, T.N. Dechow, C. Schiefer, E. von der Heyde, W. Schuette, J. Atz, R. Kaiser
Journal: Annals of Oncology (2022)
1316O Improved nationwide survival of sarcoma patients 10 years after establishment of the NETSARC+ reference center network
Authors: J-Y. Blay, A. Italiano, N. Penel, E. Bompas, F. Duffaud, C.M. Chevreau, P. Anract, C. Perrin, N. Firmin, M. Toulmonde, S. Piperno-Neumann, S. Watson, M. Rios, J.E. Kurtz, F. Bertucci, F. Le Loarer, C. Chemin, M. Morelle, F. Gouin, A. Le Cesne
Journal: Annals of Oncology (2022)
1108P Outcomes when stage IV non-small cell lung cancer (NSCLC-4) patients (pts) harboring oncogenic drivers (OD) are treated initially without tyrosine kinase inhibitors (TKI)
Authors: R. Choksi, R. Smith, M. Johnson, L. Gordan, M. Xue, P. Varughese, N. Dorrow, B. Wang, V. Vaidya, A. Vasudevan, M. Gart, H. Gierman, J. Scott
Journal: Annals of Oncology (2022)
1305P Landscape and clinical significance of germline pathogenic variants (PV) in pancreatic cancer (PC)-predisposing genes in PC patients
Authors: A. Gandini, L. Pastorino, M. Ponzano, S. Puglisi, R. Borea, M. Cremante, M. Grassi, W. Bruno, B. Dalmasso, V. Andreotti, I. Vanni, E. Allavena, F. Catalano, V. Martelli, A. Pastorino, M.L. Iaia, G. Fornarini, M.S. Sciallero, A. Puccini, P. Ghiorzo
Journal: Annals of Oncology (2022)
1106P Capmatinib for METex14 non-small cell lung cancer patients: Results of the real-world study IFCT-2104 CapmATU
Authors: M. Ferreira, L. Greillier, A. Swalduz, A.C. Toffart, J. Raimbourg, V. Gounant, S. Couraud, G. De Chabot, S. Friard, J. Hureaux, L. Odier, M. Wislez, P. Missy, F. Morin, V. Westeel, A. Cortot
Journal: Annals of Oncology (2022)
1176P Open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC)
Authors: J.F. Vansteenkiste, I. Demedts, E. Pons-Tostivint, B. Biesma, F. Borm, B. Colinet, K. Cuppens, S. Derijcke, L. Greillier, J. Jürgens, D. Moro-Sibilot, M. Pérol, M. Sebastian, M. Skrzypski, W. Theelen, C. Van De Kerkhove, M. Collodoro, J. Plumas, C. Debruyne, A. Sibille
Journal: Annals of Oncology (2022)
1190TiP Pharmacokinetics, efficacy, and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)
Authors: H.A. Yu, F. Cantero, B. Kim, M. Lee, E. Wu, D.W. Sternberg, P.A. Jänne
Journal: Annals of Oncology (2022)
1142P The influence of food with different fat concentrations on alectinib exposure: A randomized cross-over pharmacokinetic trial
Authors: D. Lanser, M.G.D. Veerman, S. De Leeuw, E. Oomen-de Hoop, M. Paats, S.L. Koolen, A-M.C. Dingemans, R.H. Mathijssen
Journal: Annals of Oncology (2022)
1085P Evaluation of blood tumor mutation burden for efficacy of second-line atezolizumab treatment in non-small cell lung cancer: BUDDY
Authors: C-K. Park, H.R. Jun, H-J. Oh, J-Y. Lee, H. Cho, Y-C. Kim, J.E. Lee, S.H. Yoon, C.M. Choi, J.C. Lee, S.Y. Lee, S.Y. Lee, S-M. Chun, I-J. Oh
Journal: Annals of Oncology (2022)
1358O Clinical qualification of transcriptome signatures for advanced prostate cancer (APC) starting androgen deprivation therapy (ADT) with or without abiraterone acetate and prednisolone (AAP): An ancillary study of the STAMPEDE AAP trial
Authors: M. Parry, E. Grist, C. Brawley, J.A. Proudfoot, L. Mendes, S. Lall, A.P. Hoyle, A. Sachdeva, Y. Liu, C. Amos, M.R. Sydes, R. Jones, M.K. Parmar, F. Feng, C.J. Sweeney, N. Clarke, E. Davicioni, N.D. James, None L. Brown, G. Attard
Journal: Annals of Oncology (2022)
1113P Real-world multicentre cohort of 1L pembrolizumab alone or in combination with platinum-based chemotherapy in NSCLC PD-L1 ≥ 50%
Authors: E. Pons-Tostivint, P. Hulo, V. Guardiolle, L. Bodot, A. Rabeau, M. Porte, S. Hiret, P. Demontrond, H. Curcio, A. Boudoussier, R. Veillon, M. Mayenga, C. Dumenil, P-A. Gourraud, J. Mazieres, J. Bennouna
Journal: Annals of Oncology (2022)
1207P Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study
Authors: Y. Li, A. Zhou, S. Liu, M. He, K-N. Chen, Z. Tian, H. Chen, H. Tian, Y. Yu, W. Qu, L. Xue, S. Wang, F. Bie, B. Zhou, H.Y. Huang, Y. Fang, B. Li, X. Dai, S. Gao, J. He
Journal: Annals of Oncology (2022)
1211P A multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (EPOC1802)
Authors: H. Bando, S. Kumagai, D. Kotani, M. Saori, T. Habu, T. Tsushima, H. Hara, S. Kadowaki, K. Kato, K. Chin, K. Yamaguchi, S-I. Kageyama, H. Hojo, M. Nakamura, H. Tachibana, M. Wakabayashi, M. Fukutani, N. Fuse, H. Nishikawa, T. Kojima
Journal: Annals of Oncology (2022)
1147P Effects of the use of antibiotics or antacids on chemoimmunotherapy prognostic factors in patients with advanced non-small cell lung cancer: A propensity-score-matched analysis
Authors: K. Tamura, Y. Okuma, A. Fukuda, K. Masuda, Y. Shinno, T. Yoshida, Y. Goto, H. Horinouchi, N. Yamamoto, Y. Ohe
Journal: Annals of Oncology (2022)
1355P Clinical trial enrollment among lung cancer patients: A real-world multicenter analysis
Authors: M.L. Reale, E. Capelletto, C. Buttigliero, P. Bordi, S. Ricciardi, L. Belluomini, E. Garbo, A. Leonetti, A. Lombardi, A. Dodi, V. Napoli, M. Casali, D. Soregaroli, J. Insolda, P. Bironzo, M. Tiseo, M.R. Migliorino, S. Pilotto, F. Passiglia, S. Novello
Journal: Annals of Oncology (2022)
1160P Survival impact of second-line immune checkpoint inhibitors in the elderly patients with advanced squamous non-small cell lung cancer: Post-hoc analysis from a CAPITAL study
Authors: Y. Kogure, A. Kada, H. Hashimoto, S. Atagi, Y. Takiguchi, H. Saka, N. Ebi, A. Inoue, T. Kurata, Y. Fujita, Y. Nishii, T. Shibayama, H. Itani, T. Endo, N. Yamamoto, A. Gemma
Journal: Annals of Oncology (2022)
1349P A decade comparison of regulatory decision patterns for oncology products to all other non-oncology products between Swissmedic, EMA and FDA
Authors: U-P. Rohr, M. Iovino, L. Rudofsky, Q. Li, S. Juritz, A. Gircys, O. Wildner, M. Bujar, S. Dalla-Torre, A. Wolfer
Journal: Annals of Oncology (2022)
1295TiP Investigation of calcium electroporation (CaEP) therapy in malignant cutaneous and subcutaneous tumours: A non-randomized phase II clinical trial of a novel palliative therapy
Authors: M. Pervan, M. Vissing, H. Princk, J. Ploeen, K. Vestergaard, M. Schnefeldt, S. Rafaelsen, C. Lindhardt, L.H. Jensen, A. Rody, J. Gehl
Journal: Annals of Oncology (2022)
1253P Safety and efficacy of Wnt inhibition with a DKK1 inhibitor, DKN-01, in combination with atezolizumab in patients with advanced oesophagogastric adenocarcinoma: Phase IIa results of the WAKING trial
Authors: F.S. Turkes, R. Crux, A. Tran, E. Cartwright, I. Rana, E. Johnston, A. Dunlop, J. Thomas, A. Smith, E. Smyth, C. Fribbens, S. Rao, D. Watkins, I. Chau, N. Starling, D. Cunningham
Journal: Annals of Oncology (2022)
1229P A multicenter phase II study of sotigalimab (CD40 agonist) in combination with neoadjuvant chemoradiation for resectable esophageal and gastroesophageal junction (GEJ) cancers
Authors: A.H. Ko, M. Noel, J. Chao, D. Sohal, M. Crow, P.E. Oberstein, A. Scott, A. McRee, C. Rocha Lima, L. Fong, B. Keenan, E. Filbert, F.J. Hsu, V. Shankaran
Journal: Annals of Oncology (2022)
1342P Pharmacoeconomics in the antineoplastic therapy sector of a public hospital in the Brazilian Amazon aiming at cost minimization: Quantitative analysis
Authors: K. Borges, B.R. Almeida, G.R. Almeida, C. Borges Junior, S. Queiroz, J.N. Quaresma, E. Negrão, K.M. Penalber
Journal: Annals of Oncology (2022)
1311P Penile cancer in North-West England: A 5-year analysis of epidemiology, risk factors and outcomes in a supraregional centre
Authors: N. Peters, J.A. Scott, A. Issa, C. Fankhauser, E. Lee, J. Churchill, P. Oliveria, A. Tran, M. Lau, A. Parnham, V. Sangar, D.M. Graham
Journal: Annals of Oncology (2022)
1141P A multicenter study of incidence of drug-induced lung disease in first-line osimertinib therapy and continuation of osimertinib administration
Authors: C. Mimura, M. Tachihara, K. Kaneshiro, Y. Kono, S. Fujimoto, Y. Hatakeyama, R. Dokuni, N. Iwamoto, K. Matsumura, K. Kobayashi
Journal: Annals of Oncology (2022)